IL2 and neoplasm: These findings are consistent with previous work showing limited benefit of ICIs in non-immunogenic models52 and further support the notion that a pre-existing tumor-specific T cell response is crucial for the effectiveness of IL-2-based immunotherapy in combination with ICI.